On Friday 24 May 2019, OssDsign was listed on Nasdaq First North. In connection with the listing, the company has carried out an issuance of new shares amounting to SEK 151.3 million, which was oversubscribed. Setterwalls has been legal advisor to the company throughout the listing process. Erik Penser Bank was financial adviser to the company and has also been engaged as Certified Adviser. SV Ventures was co-adviser on strategic issues.
The offer in connection with the listing consisted of an issuance of new shares amounting to SEK 151.3 million, with an overallotment option of an additional SEK 22.7 million directed to the general public in Sweden and institutional investors in Sweden and abroad. The price in the offer was SEK 27.50 per share, which corresponds to a company value of approximately SEK 336 million before the offering.
OssDsign develops and markets innovative implants for improved healing and treatment of bone defects. The foundation of the company is a patented bioceramic material which during the healing process is transformed into bone tissue. OssDsign designs, manufactures and sells patient-specific implants for treating injuries and defects in the skull and face. OssDsign’s Technology is the result of a collaboration between clinical researchers at Karolinska University Hospital and material scientists at Ångström Laboratory at Uppsala University.